INTRODUCTION
The number of elderly individuals suffering from type 2 diabetes (T2DM) is continuously growing worldwide. This is related to the overall aging of the population as well as to a continuous increase in the prevalence of T2DM with age, reaching about 20% in adults aged 75 years or older [1] . These elderly patients have an increased prevalence of T2DM-related morbidity and mortality, physical disability and frailty, cognitive disorders and, in particular, micro-and macrovascular co-morbidities, such as congestive heart failure and renal impairment (RI) [2] .
Diabetes is the leading causes of chronic kidney disease [3] , with T2DM patients accounting for about 1/3 of all cases of end stage renal disease (ESRD) requiring dialysis [4] . In addition, there is also an age-related decline in kidney function [5] . Ultimately, between 25% and 40% of patients with T2DM will develop RI [6] . In a large-scale French survey, for example, 28% of the population of patients with T2DM C65 years had moderate RI and this increased to 37% for patients aged 75-79 years [7] .
The elderly population with T2DM and moderate or severe RI is a uniquely fragile population and effective treatment in this vulnerable population poses special challenges.
These include a high prevalence of polypharmacy, which increases the risk of drug-drug interactions, presence of multiple co-morbidities, and the paucity of clinical data in this population. Importantly, treatment options are more limited and/or complex in this population due to contraindications, differential clearance and/or metabolism of anti-hyperglycemic agents, need for dose adjustment and/or regular monitoring. In addition, there is a higher risk for side effects, in particular, a high susceptibility and dangerousness of hypoglycemia. The risk of hypoglycemia associated with drug treatment (insulin secretagogues and insulin) increases markedly with age [2, 8] and hypoglycemia in the elderly is associated with more severe consequences and complications [2] . The risk of adverse effects is further increased by a marked unawareness of hypoglycemia in the elderly population, leading to more frequent and severe events [9, 10] . Furthermore, RI is also associated with an increased incidence of hypoglycemia due to decreased renal neoglycogenesis [11] . For example, in a retrospective cohort analysis, the incidence of hypoglycemia (glucose \70 mg/dL) was 10.72 events per 100 patient-months in diabetic patients with chronic kidney disease versus 5.33 in those without chronic kidney disease [12] . Additionally, RI is associated with differential clearance and/or metabolism of several anti-hyperglycemic agents; in particular, consequent overexposure to insulin secretagogues is often linked to an increased risk of hypoglycemia [13] . Similarly, the difficulty with insulin dose selection due to impaired catabolism and clearance of exogenous insulin in patients with RI further increases the risk of hypoglycemia [13] .
Vildagliptin is an inhibitor of dipeptidyl peptidase 4 (DPP-4) that extends the mealinduced increases in the levels of the incretin hormones, glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), thereby improving the sensitivity and responsiveness of pancreatic a-cells and b-cells to glucose [14] . This results in glucose-sensitive modulation of insulin and glucagon secretion, improving both fasting and postprandial glycemic control, with a low risk of hypoglycemia [14] . A hypoglycemia risk similar to placebo has consistently been seen with vildagliptin across a wide spectrum of patients/disease [15] , including elderly patients [2, 16] , patients with RI [17] [18] [19] and/or patients treated with insulin [20] . This included data from a dedicated 24-week study of vildagliptin 50 mg qd in patients with moderate or severe RI [17] . In this large study *20% of patients were 75 years or older, which provided an opportunity to assess the efficacy and tolerability of vildagliptin in this particularly vulnerable and difficult-to-treat elderly T2DM patient population with RI. Accordingly, the authors report here the experience with vildagliptin in patients C75 years with T2DM
and moderate/severe RI based on a subanalysis of the afore-mentioned study [17] .
MATERIALS AND METHODS

Patients and Study Design
This was a post hoc sub-analysis of data from a previously described [17] 
Ethics and Good Clinical Practice
The study underlying this sub-analysis was 
RESULTS
Demography
One hundred and five patients [50 in the vildagliptin (50 mg qd) group and 55 in the placebo group] with moderate or severe RI and aged 75 years or older at study entry were included in this analysis. 
EFFICACY
In the patients C75 years with T2DM and moderate/severe RI receiving vildagliptin 50 mg qd added to background therapy, the AMD in HbA 1c from baseline (7.8% ± 0.2%) to week 24 endpoint was -1.0% ± 0.2%, while in the patients receiving placebo added to background therapy the AMD from baseline (7.9% ± 0.1%) to endpoint was -0.2% ± 0.2% (Fig. 1a) . This resulted in a significant betweengroup difference (vildagliptin-placebo) of -0.8% ± 0.2% (p\0.001). 
26.3%).
FPG also decreased with vildagliptin. The AMD in FPG in the vildagliptin group was -1.1 ± 0.6 mmol/L (baseline 8.9 ± 0.5 mmol/ L); however, the between-treatment difference (-0.9 ± 0.5 mmol/L) did not achieve statistical significance (p = 0.088).
Body weight remained stable in the vildagliptin group; baseline weight averaged 81.1 ± 2.0 kg and the AMD was 0.4 ± 0.7 kg. In the placebo group, the AMD was -1.0 ± 0.7 kg from a baseline of 79.8 ± 1.9 kg (p = 0.015 vs. vildagliptin).
The markedly lower glucose level achieved with vildagliptin vs. placebo added to background therapy was not associated with an increased risk of hypoglycemia. Figure 1b 
Safety and Tolerability
The overall AE profile was similar in elderly patients with moderate/severe RI receiving vildagliptin or placebo ( AE adverse event, n number of patients with an AE, SAE serious adverse event, SOC system organ class a C10% in the study 
DISCUSSION
The present sub-analysis evaluated vildagliptin in the uniquely vulnerable elderly population C75 years with T2DM and moderate or severe RI, many of whom (nearly 70%) were treated with insulin. The main finding was that vildagliptin was efficacious, with no increase in the rate of hypoglycemia compared to placebo despite a marked improvement in glycemic control. The magnitude of the glucose-lowering seen in this subgroup (HbA 1c reduction of -1.0% from a baseline of 7.8%) was similar to that seen previously in patients C75 years with mostly normal renal function or mild RI receiving vildagliptin monotherapy or add-on therapy to metformin (-0.9% to -1.1%) [16] or in a population with severe RI with a mean age of 64 years receiving background insulin therapy (-0.9%) [18] , which was also reported to be consistent with that seen for vildagliptin in the general population in monotherapy or combination therapy studies. Relative to placebo, the decrease in HbA 1c (-0.8%) was clinically meaningful, with more than half of the vildagliptin-treated patients reaching an HbA 1c B7.5%, regarded an appropriate target for this patient population [3, 21, 22] . Thus, the metabolic derangements clearly manifested in this patient population with advanced age, RI, and long-standing mainly insulin-treated T2DM [23] did not adversely affect the efficacy of vildagliptin. The small HbA 1c reduction (-0.2%) seen in the control group is likely a study effect and not unusual for patients entering a placebo-controlled trial.
Hypoglycemia is a major limiting barrier to good glycemic control even in the general population [15] . In light of the markedly increased risk of hypoglycemia, including severe hypoglycemia, in a highly vulnerable patient population of advanced age, with RI and significant insulin use [2, [8] [9] [10] [11] [12] and given the more severe consequences of hypoglycemia in these patients (including events like falls and fractures [2] ), as well as the potential CV risk associated with severe hypoglycemia [2, 24] , the finding that there was no increase in the rate of hypoglycemia with vildagliptin despite the meaningful decrease in mean HbA 1c (7.8% to 6.8%) is noteworthy. The rate of confirmed hypoglycemia was 0.49 vs. 0.96 events per patient-year with vildagliptin and placebo, respectively, with a very low incidence of severe hypoglycemia (1 patient on multiple insulin injections in the vildagliptin group, precipitated by alcohol consumption, and 0 patients in the placebo group) and no discontinuations due to hypoglycemia. While an improvement in glycemic control in the range reported in the current analysis would generally be expected to be associated with an increase in hypoglycemia, in particular, in the patient population studied, the protection against hypoglycemia seen with vildagliptin has a mechanistic basis, likely being mediated via a GIP-induced increase in glucagon levels whenever glucose levels fall into the hypoglycemic range [14, 20] . Vildagliptin treatment extends the physiological mealrelated increases of the incretin hormones into the inter-meal and overnight periods and vildagliptin was shown to enhance the glucagon counter-regulatory response to hypoglycemia during a stepped clamp versus placebo in drugnaïve patients with T2DM [14, 25] .
Consistent with the weight neutrality generally reported for vildagliptin [26] including in insulin-treated patients [20] , there was only a minimal weight change (0.4 kg) reported for vildagliptin when added to background therapy in the elderly patient group with moderate/severe RI.
The safety and tolerability of vildagliptin in a wide range of disease stages including pooled analyses from a large clinical database was assessed in detail previously [16, 17, 20, [27] [28] [29] 
